Intravitreal triamcinolone and elevated intraocular pressure.
OBJECTIVE
To ascertain whether intravitreal triamcinolone given for subretinal neovascularization is associated with an ocular pressure rise.


METHODS
A total of 113 patients with angiographically proven subretinal neovascularization were enrolled into a prospective study of the effects of intravitrea triamcinolone. Intraocular pressure was one of the parameters studied.


RESULTS
Approximately 30% of the study group developed a significant rise (> or =5 mm Hg) in intraocular pressure above baseline during the first 3 months.


CONCLUSIONS
Patients considering this form of treatment should be fully informed of the known risks of intraocular injections of steroids.
Wingate
R J
RJ
rwingate@internet-australia.com
Beaumont
P E
PE
D005451:Fluorescein Angiography; D005654:Fundus Oculi; D005938:Glucocorticoids / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007267:Injections; D007429:Intraocular Pressure / Q000187:drug effects*; D008268:Macular Degeneration / Q000150:complications; D009798:Ocular Hypertension / Q000139:chemically induced*; D011446:Prospective Studies; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D012307:Risk Factors; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000009:adverse effects* / Q000627:therapeutic use; D014822:Vitreous Body
D005938:Glucocorticoids; D014222:Triamcinolone Acetonide